Sato Shuichi, Miyake Tatsuya, Kataoka Masatoshi, Isoda Kazuki, Yazaki Tomotaka, Tobita Hiroshi, Ishimura Norihisa, Kinoshita Yoshikazu
Department of Gastroenterology and Hepatology, Shimane University Faculty of Medicine, Japan.
Intern Med. 2017 Nov 1;56(21):2887-2890. doi: 10.2169/internalmedicine.8791-16. Epub 2017 Sep 25.
The efficacy of repeated lusutrombopag administration for thrombocytopenia in patients with chronic liver disease who undergo two or more planned invasive procedures is unknown. We herein report our findings regarding the effects of repeated lusutrombopag administration given to avoid platelet transfusion in a patient with chronic liver disease and thrombocytopenia. The platelet count showed a positive response to lusutrombopag treatment prior to the initial invasive procedure to treat a hepatoma, so platelet transfusion was not necessary. In conclusion, lusutrombopag may be a useful drug for patients with thrombocytopenia to avoid platelet transfusion in those undergoing two or more planned invasive procedures.
对于接受两次或更多次计划性侵入性操作的慢性肝病患者，重复使用芦曲泊帕治疗血小板减少症的疗效尚不清楚。我们在此报告关于对一名患有慢性肝病和血小板减少症的患者重复使用芦曲泊帕以避免血小板输注的效果的研究结果。在最初治疗肝癌的侵入性操作之前，血小板计数对芦曲泊帕治疗呈阳性反应，因此无需进行血小板输注。总之，对于血小板减少症患者，芦曲泊帕可能是一种有用的药物，可避免在接受两次或更多次计划性侵入性操作的患者中进行血小板输注。
